NCT03856099 — "TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab" trial site landscape

Public-registry site landscape for NCT03856099, “TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab”, a Recurrent Glioblastoma study sponsored by PharmAbcine. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT03856099 (registry record)
Study title	TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab
Official title	A Multicenter, Open-Label, Phase Ⅱ Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients With Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy
Sponsor	PharmAbcine
Condition(s)	Recurrent Glioblastoma
Phase	PHASE2
Listed sites	3
Site countries	United States, Australia

Patient-friendly overview of this study: eichor.com/study/NCT03856099.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT03856099 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →